Charmacy Pharmaceutical Co., Ltd.

HKEX:2289.HK

8.35 (HKD) • At close September 16, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) HKD.

2023 Q42023 Q22022 Q42022 Q22021 Q42021 Q22020 Q42020 Q22019 Q42019 Q22018 Q42018 Q22017 Q42017 Q22016 Q42016 Q22015 Q42015 Q22014 Q42014 Q22013 Q4
Revenue 2,134.5592,269.0742,288.21,887.0791,800.6041,993.0142,130.9511,860.7591,784.6951,708.0881,913.2582,021.9882,191.8941,903.9421,891.8321,777.9491,761.7361,635.3971,564.5331,449.526753.515
Cost of Revenue 1,984.892,130.3612,141.1171,765.5531,698.3971,861.1042,012.8671,741.4411,698.1141,574.0211,824.9651,875.1592,109.2141,779.2021,811.5841,678.3511,680.6471,551.7841,499.4971,378.121719.405
Gross Profit 149.669138.713147.083121.527102.207131.91118.085119.31886.581134.06788.293146.82982.68124.73980.24999.59881.08983.61365.03671.40534.11
Gross Profit Ratio 0.070.0610.0640.0640.0570.0660.0550.0640.0490.0780.0460.0730.0380.0660.0420.0560.0460.0510.0420.0490.045
Reseach & Development Expenses 000000000000000000000
General & Administrative Expenses 28.64318.8931.42318.31329.44718.95529.23816.46224.0322.47428.33225.82726.00523.49817.09421.66117.70622.67421.55615.6069.291
Selling & Marketing Expenses 59.46563.00258.93453.89751.1352.31845.2840.69541.28536.11537.836.18335.85832.2229.64322.13521.79218.50420.09815.6598.939
SG&A 88.45982.34592.5672.48980.03871.52182.77960.26470.14858.00267.29462.89264.88354.67448.85143.79639.49841.17841.65431.26518.23
Other Expenses 000000000000000000-0.216-0.128-0.128
Operating Expenses 95.33489.1435.3180.77484.88478.53390.21964.72474.68364.1274.94868.60467.87357.68146.64943.58865.31838.3641.71830.68918.102
Operating Income 56.51651.7648.99744.4918.12656.29731.93656.1413.28971.90918.02481.05715.68468.03430.02253.43741.59142.43523.38240.1417.192
Operating Income Ratio 0.0260.0230.0210.0240.010.0280.0150.030.0070.0420.0090.040.0070.0360.0160.030.0240.0260.0150.0280.023
Total Other Income Expenses Net -24.254-16.60247.209-18.642-19.676-21.767-18.939-14.395-15.862-14.29-18.683-16.742-13.734-10.126-3.17-4.207-33.731-8.72-10-7.587-5.708
Income Before Tax 32.26235.15796.20625.848-1.5534.5312.99741.746-2.57457.618-0.65964.3151.9557.90826.85249.2297.8633.71513.38232.55311.484
Income Before Tax Ratio 0.0150.0150.0420.014-0.0010.0170.0060.022-0.0010.034-00.0320.0010.030.0140.0280.0040.0210.0090.0220.015
Income Tax Expense 7.278.80526.3735.2091.2588.5693.31410.8720.42215.3140.09818.9920.61614.9467.15712.4676.7358.4813.3866.1042.373
Net Income 24.99226.35369.83320.639-2.80825.9619.68330.873-2.15142.305-0.20745.641.84142.91919.69636.7631.12525.2349.99626.4499.111
Net Income Ratio 0.0120.0120.0310.011-0.0020.0130.0050.017-0.0010.025-00.0230.0010.0230.010.0210.0010.0150.0060.0180.012
EPS 0.230.240.650.19-0.0260.240.090.29-0.020.39-0.0020.420.0170.40.180.340.0140.320.120.330.11
EPS Diluted 0.230.240.650.19-0.0260.240.090.29-0.020.39-0.0020.420.0170.40.180.340.0140.320.120.330.11
EBITDA 66.3961.70261.17759.85333.52969.98943.82766.04323.28283.0227.97889.54423.03474.80535.98658.95146.16246.84628.11745.1320.177
EBITDA Ratio 0.0310.0270.0270.0320.0190.0350.0210.0350.0130.0490.0150.0440.0110.0390.0190.0330.0260.0290.0180.0310.027